Product
Gemcitabine/nab-paclitaxel
2 clinical trials
8 indications
Indication
Metastatic CancerIndication
Solid TumorIndication
Pancreatic CancerIndication
Bladder CancerIndication
Head and Neck CancerIndication
Colorectal CancerIndication
Pancreatic Cancer MetastaticIndication
Pancreatic Ductal AdenocarcinomaClinical trial
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 as a Single Agent and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Pancreatic Adenocarcinoma Signature Stratification for TreatmentStatus: Active (not recruiting), Estimated PCD: 2025-01-01